INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is associated with considerable procedure-related mortality and morbidity; yet, for patients with devastating hematologic malignancies, it provides significant opportunities for cure. [1] [2] [3] In recent years, barriers such as diminished donor availability, advanced patient age and the presence of comorbid conditions have been reduced. As a result, allo-HCT has been offered to increasing patient populations due to proliferation of transplant registries, more precise patient risk stratification, molecular HLA typing and the introduction of reduced intensity conditioning (RIC). Given the inherent selection biases, however, the relative benefit of this procedure is uncertain. Phase III comparisons between the nontransplant and allo-HCT alternatives are highly complicated, slow to recruit patients and require joint efforts of large cooperative oncology groups. The scarcity of data generated requires utilization of supplemental methods such as observational databases (for example, Center for International Blood and Marrow Transplant Research and European Group For Blood and Marrow Transplantation) and expert opinion (for example, NCCN Guidelines) as an important source for evidencebased decision making. 4, 5 Thus, appropriate interpretation of data is fundamental for the practice of allo-HCT. 6, 7 Herein we discuss common biases in current available data and practical interpretation for optimizing the assignment of patients to undergo allo-HCT. Specific situations are used to illustrate common clinical dilemmas.
THE IMPORTANCE OF LARGE STUDIES
Would you refer a 30-year-old male with standard-risk ALL in first CR1 to allo-HCT?
In the 1990s, it was customary to reserve allo-HCT only for highrisk patients and patients with standard-risk ALL were seldom considered for an allogeneic transplant in CR1. 8 The reason was that early studies of allo-HCT in ALL were relatively small and therefore underpowered to demonstrate a significant benefit. Furthermore, owing to the improving outcome in pediatric ALL, there was a widespread perception that similar results would soon follow in adults. 9 Thus, it was customary to reserve allo-HCT only for high-risk patients. Indeed, in the large French prospective LALA-94 study allo-HCT was not offered to standard-risk patients in CR1. 8 Even a retrospective report from Seattle describing 161 consecutive ALL patients who underwent allo-HCT between the years 1998 and 2006 mainly included patients in CR2 or relapse. 10 The Eastern Cooperative Oncology Group (ECOG) in the US and the Medical Research Council in Great Britain (MRC) jointly conducted a large prospective study of nearly 2000 newly diagnosed patients with ALL which confirmed the potency of the GVL effect and established a definitive role for allo-HCT in standard-risk ALL. This study showed that standard-risk patients had a better outcome if offered an allo-HCT from a matched sibling in CR1 (Figure 1 ). The benefit from allo-HCT in this group was not detected in early ALL transplant studies that were underpowered to demonstrate a significant benefit.
2 These findings were confirmed by meta-analyses 11, 12 and a Cochrane review 13 that paved the way for subsequent studies examining whether RIC is also beneficial in high-risk ALL patients.
Conclusion: Physicians should encourage patients to participate in large prospective studies even if earlier small studies failed to demonstrate a benefit from allo-HCT. Our 30-year-old patient with ALL in CR1 may well benefit from allo-SCT, though earlier small studies obscured this benefit.
INTERPRETING OUTCOME DATA IN ALLO-HCT. INCREMENTAL MORTALITY DUE TO TRANSPLANT VS CONSERVATIVE OPTIONS.
Should allo-HCT be offered to a 45-year-old female with a normal karyotype, FLT3-and NPM1-negative AML in CR1?
Paucity of prospective randomized trials makes observational studies a prominent source for transplant outcome information. Such reports neglect the anticipated outcome of nontransplant alternatives which are often underestimated biasing against choosing allo-HCT in matched patients. For example, among high-risk ALL patients the 2-year nonrelapse mortality (NRM) after allo-HCT was a prohibitive 35.6%, but patients who did not undergo a transplant had a lower, but nontrivial, NRM of 13.6%. 2 Similarly, in a report of patients under 50 years registered to the MRC AML 10, 12 and 15 trials, the NRM for patients not undergoing a transplant was 9.7%.
14 Thus, when a patient is being considered for allo-HCT, the incremental mortality over alternative nontransplant modality should be predicted. The NRM risk and feasibility of the nontransplant approach in a specific clinical scenario should be appropriately projected. Putting risk of transplant in perspective is essential for unprejudiced referral practice.
Whether or not to refer intermediate-risk AML patients in CR1 to allo-HCT is a common clinical dilemma. Most likely, the abovementioned 45-year-old woman feels well and may be reluctant to undergo allo-HCT. The combined treatment-and relapse-related death rate following transplant is high and deters physicians from recommending this treatment modality. The underlying perception is that allo-HCT is 'dangerous' and should only be conducted when no other option is available. 6 Yet, nontransplant alternative protocols are also associated with considerable relapse and mortality rates. 15 There are multiple clinical factors and scoring systems that enable prediction of TRM of allo-HCT. [16] [17] [18] [19] [20] All models consistently predict that a young, otherwise healthy individual in CR1 has a 1-year post-transplant TRM risk of about 15-20%. It should be also mentioned that in multiple acute leukemia studies, a mortality risk of 1-3% was associated with each consolidation cycle; thus, the cumulative TRM over four cycles of consolidation is 10%. This must be considered in light of the success rate of allo-HCT, which is significantly higher if the transplant is performed during CR1 than after disease relapse. Furthermore, the likelihood that patients who experience relapse will achieve a second CR is only in the range of 15-50% depending on the duration of the CR1. [21] [22] [23] [24] Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) demonstrating promising outcomes with allo-HCT for AML (Figure 2a ) in CR2 in adults aged 18-50 years do not adequately reflect the major obstacles that patients need to overcome following relapse of leukemia to become eligible for allo-HCT. 21 Indeed, OS rates of all AML patients included in eight Eastern Cooperative Oncology Group prospective studies who later experienced relapse were reported to be as low as 11% in patients o 55 years and only 5% in patients who were 455 years, reflecting the low frequency with which patients who have relapsed AML actually reach and survive curative transplants. (Figure 2b ). In adults with standardrisk ALL the OS benefit from allo-SCT was recognized only in the largest prospective joint study conducted by ECOG and MRC, which was the only prospective transplant study that also included standard-risk ALL patients. Reproduced with permission from Goldstone et al. Interpreting outcome data Y Ofran et al critical interpretation of available data. For example, the MRC reviewed the outcome of 3919 patients aged 16-49 years who participated in prospective MRC trials and did not receive a transplant while in CR1. 14 The authors found that after relapse, 19% of patients who did not undergo allo-HCT while in CR1, will survive. These results reflect an improvement in our ability to rescue relapsing patients. However, to confirm the superiority of nontransplant approaches in CR1, the following issues should be taken into consideration. As reported by the MRC (Figure 3) , the cumulative long-term survival of an intermediate-risk AML patient in CR1 was 41% after consolidation therapy alone. In contrast, of the 692 similar patients who underwent allo-HCT in CR1, the 5-year OS rates were 64 and 65% if transplantation utilized a matched sibling donor (full ablative or RIC, respectively) and 45% if a MUD (matched unrelated donor) was employed. As these data included allo-HCT conducted between 1988 and 2009 it is reasonable to assume that current MUD results may be better, based on molecular matching. Thus, for a patient who has no comorbidities and is now in CR1 from intermediate-risk AML, deferring allo-HCT during CR1 for intermediate-risk patients comes with a price of potentially reducing the expected 5-year OS from 65 to 41%. Similar results were reported from a comparison of 185 matched pairs of patients o 60 years in CR1 who underwent allo-HCT or received conventional post-remission therapy. OS at 7 years was 58% for the allo-HCT group and 46% (P = 0.037) for the conventional post-remission treatment group. 25 Recently, the European LeukemiaNet AML Working Party issued a consensus statement integrating patient-specific relapse-risk reduction with the incremental anticipated mortality with allo-HCT compared with serial consolidation cycles. 26 In brief, the lower the risk of mortality from transplant, the more justified is transplant for intermediate-risk patients. For a patient with comorbidities the transplant-related risk is high and therefore, allo-HCT should be reserved for poor prognosis leukemias (Table 1) .
Conclusion: Young intermediate-risk leukemia patients in CR1 like our 45-year old woman may have a greater chance for longterm survival using allo-HCT. Assessing the incremental mortality of allo-HCT is crucial.
INTENTION-TO-TREAT BIASES IN PROSPECTIVE TRANSPLANT TRIALS
Given the many uncertainties in interpreting retrospective data (Table 2) , prospective trials are preferred. However, prospective transplantation trials are also prone to biases. Studies that recruit patients from time of disease diagnosis are more likely to represent real world transplanted populations thereby avoiding biases from pretransplantation therapy and factors, time-totransplantation and the early deaths (Table 2) . Unfortunately, those studies often report a high percentage of deviations from assigned treatment and therefore are subject to an intent-to-treat bias. 27 This phenomenon is particularly relevant for autologous transplant studies for acute leukemia and, to a lesser degree, for allogeneic transplants where up to 50% of patients do not receive their assigned treatment; [28] [29] [30] hence, in transplantation studies actual adherence to assigned therapy is a major factor determining the quality of data generated by prospective studies.
PATIENT SELECTION BIASES When is someone too old for transplant?
Should one offer a transplant to a 69-year-old woman with intermediate-risk AML in CR1, who is otherwise active and healthy and has a fully matched 55-year old sibling as a potential donor? The incidence of hematologic malignancies, including AML, ALL and MDS, increases with age. Moreover, for patients over the age of 60 years, cure from these conditions is uncommon with chemotherapy alone. 31 Nevertheless, prospective transplantation studies traditionally excluded older adults. A Medicare populationbased study, conducted between 2000 and 2007, included 5480 AML patients aged 65 years and older, and identified only 46 patients who underwent allo-HCT (0.8%). 32 Cooperative groups have long noted the difficulty of prospectively accruing older adults to transplant studies. Obviously, these results correspond to a highly select group of older patients. Yet, within this group, OS of allo-HCT recipients aged 65-69 years and 70-74 years was similar (median survival time of 29 vs 22 months, respectively) but strongly associated with the comorbidity index (29 vs 8 months for patients with high comorbidity scores, respectively). A report from the Dana Farber Cancer Institute on 158 consecutive patients with hematologic malignancy aged ⩾ 60 years (median 63 years; range 60-71 years) who underwent fludarabine/BU-based RIC allo-HCT, demonstrated comparable results among patients younger and older than 65 years. 33 A retrospective study of 152 Japanese AML patients aged 50-70 years who underwent allo-HCT in CR1 compared with 884 patients treated with chemotherapy showed a reduction in the cumulative incidence of relapse after allo-HCT from 62 to 22% 34 ( Figure 4 ). Despite a higher TRM with allo-HCT, the reduction in relapse incidence translated into a significant improvement in the 3-year OS from 51 to 62% (P = 0.012). The beneficial effect of allo-HCT was most pronounced in the intermediate-risk group and nonsignificant in the higher-risk cohort owing to the substantial relapse incidence even after allo-HCT. In a recent report from the European Group for Blood and Marrow Transplantation, among 719 older-age MDS patients (median 58 years; range 50-73 years) who received allo-HCT from related (n = 555) or unrelated (n = 164) donors, the 5-year OS was 33% for patients receiving sibling donor transplants. 35 By multivariate analysis, disease-related parameters, but not patient age significantly affected post-transplant survival (Table 3) . Prospective transplantation data in older patients are lacking. Given the 80% relapse rate and the 23% 5-year survival reported with chemotherapy alone in older age groups with AML, 36 these retrospective reports are encouraging. In the absence of significant comorbidities, allo-HCT should therefore be considered for select older patients. 37, 38 Conclusion: Although customary practice may bias against allo-HCT in patients with advanced age, available data suggest that in a select population it may offer survival benefit.
STUDY COHORTS RECRUITED FROM NONCOMPARABLE POPULATIONS
Should allo-HCT be offered to a 65-year-old man, diagnosed with MDS presenting with symptomatic anemia, trisomy 8 and 11% of blasts in his BM who also suffers from mild but stable chronic renal failure? Allo-HCT studies have demonstrated that age, graft cell dose, presence of CMV and disease status at transplantation may influence outcomes. The decision whether a patient with mild kidney, lung or heart disease should be denied a transplant very much depends on subjective anticipation of transplant risks and benefits. A painstaking selection of candidates by large transplantation centers may make outcome reports less applicable to smaller centers 6,7 ( Figure 5 ). High-risk patients may be rejected by some transplantation centers and will be over-represented in outcome reports from centers with less stringent selection criteria. Awareness of this bias led the CIBMTR to categorize US centers as levels 1-5 based on the risk status of the patients they transplant -1 being low risk, 5 being high risk. The 1-year survival ranges from 40 to 50% for level 4/5 centers to 470% for level 1 centers. 39 In addition, transplant centers rely on referral practice of their affiliated hematologists. A survey among select community 
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Interpreting outcome data Y Ofran et al oncologists detected significant barriers to referral for allo-HCT. 40 In an albeit small retrospective study of a cancer registry in Manitoba, Canada, only 4 of 14 high-risk myelodysplastic syndrome (MDS) patients eligible for transplantation were referred to the nearby transplantation center, two subjects only after their disease had transformed to AML. 41 Multicenter international studies may overcome such biases.
For example, it is worth considering whether results of a retrospective study comparing the outcome of patients transplanted in the USA and Germany with results of patients from France who received azacitidine, 3 could be applicable to our 65-year-old patient. This trial suggested a small survival advantage for allo-HCT compared with azacitidine therapy in medically fit patients aged 60-70 years. Of note, high-risk MDS patients are 11 times more likely to be assigned for chemotherapy or hypomethylating agents than to allo-HCT in France compared with the USA (55.5% vs 5.1%, respectively). 42 Such a significant difference may reflect the higher probability of being treated in specialized MDS centers in France, whereas in the USA many lowrisk patients are treated by community oncologists only. Indeed, although presenting with the same disease score, the two groups are not comparable. Despite a comparable time lag from diagnosis to treatment, leukemic transformation occurred before therapy initiation in 9% of azacitidine-treated patients and in 42% of the allo-HCT cohort. As survival curves of the two cohorts did not separate until~2 years after the start of therapy, 3 the benefit from allo-HCT for patients similar to the one mentioned above may be even higher than reported.
Important details of pretransplant history such as the number and type of therapies preceding transplant, may also potentially bias outcomes. For example, the pretransplant administration of azacitidine in high-risk MDS patients may affect allo-HCT results. 43, 44 In addition, supportive care measures such as the number of blood transfusions administrated before transplantation may lead to severe iron overload, thereby affecting the transplant outcome. 45, 46 Thus, careful attention to patient selection and pretransplantation history and therapy are crucial for informed decision making and projection of transplant outcomes. Interpreting outcome data Y Ofran et al
For the above mentioned 65-year-old patient, allo-HCT carries a survival benefit. Azacitidine therapy may be considered as a bridge to transplantation therapy.
DOES THE INTENSITY OF THE CONDITIONING REGIMEN MATTER?
A 48-year-old patient with AML secondary to prior therapy for breast cancer is referred to you for allo-HCT from her matched sister whereas in CR1. She prefers to undergo RIC. What will you advise? As recently as 15 years ago, patients 455 years were often considered ineligible for allo-HCT. A significant breakthrough was made when two separate groups demonstrated that allo-HCT with RIC is feasible. 47, 48 Centers which adopted fludarabine-based RIC protocols reported a significant reduction in treatment-related immediate toxicity and mortality and a reduction in acute GVHD rates. [49] [50] [51] [52] [53] [54] As most AML patients are older than the upper age limit for myeloablative transplants, RIC protocols were accepted with enthusiasm allowing transplant centers to raise the age limit above 60 years and even higher for select, medically fit patients. 55, 56 However, using this strategy, relapse rates were reported to be higher than those reported for myeloablative conditioning. Large retrospective studies confirmed these earlier observations of reduced early morbidity, toxicity and mortality. Yet, this benefit was offset by the excess relapse rate. 57 In the absence of prospective data, the common practice in recent years was to assign patients for RIC according to age and comorbidities. Recently a relatively small, phase III German multicenter prospective trial randomized 195 young AML patients in CR1 between RIC and myeloablative conditioning. This trial, which unfortunately closed prematurely owing to slow accrual, appeared to confirm the finding of previous retrospective trials that 3-year OS and EFSs following RIC and myeloablative conditioning were equivalent. 58 Of special attention are the competing risks of TRM and NRM. Focusing on prolonged survival, the prospective German study reported identical NRM in both arms after 3 years. This appeared to contradict multiple reports of lower TRM with RIC. However, for patients aged 41-60 years, a hazard ratio for early mortality rate of 0.23 was reported (95% confidence interval (CI) 0.07-0.78; P = 0.02) for RIC with an inpatient mortality rate of 0% vs 12% for myeloablative transplants. The reported relatively low and identical relapse rate should be assessed with caution as it may reflect that the study only recruited a relatively 'good' patient population where the intensity of conditioning is of less importance. First, all patients were young and in CR1. Second, as patients were recruited while in CR1, investigators may have selected patients they anticipated to be at high risk for relapse assigning them for a regular full conditioning allo-HCT. Until results of the ongoing BMT CTN prospective comparison 59 are available, the merit of myeloablative vs RIC for AML and MDS patients remains debatable.
Conclusion: Despite a prospective randomized trial reporting similar long-term survivals, advantages for both reduced and myeloablative conditioning regimens have been identified. In addition to careful attention to treatment history and comorbidities a thorough consideration of the relative benefits and risks of each approach is recommended to ensure assignment to optimal treatment regimens. For a fit patient who is anticipating highrelapse risk like the above mentioned 48-year-old woman, even results of prospective randomized trials may be nonapplicable.
IS THERE A PREFERRED METHOD FOR PROCUREMENT OF HEMATOPOIETIC PROGENITOR CELLS?
Peripheral blood (PB)-derived hematopoietic progenitor cell collection became available 420 years ago. The use of G-CSF yields a higher content of donor T cells in the graft raising concern for potential exacerbation of GVHD. Indeed, in several randomized trials, mobilized PB cells resulted in faster and more robust engraftment but at the cost of increased acute and chronic GvHD compared to allo-HCT transplants using bone marrow as the graft source. [60] [61] [62] [63] [64] [65] [66] Despite these published data, most likely owing to its logistical simplicity and preference by donors, the use of PB cells has increased substantially over the past decade and now accounts for up to 80% of hematopoietic cell donations.
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Researchers from North America and Europe who were concerned about the safety of cytokine-stimulated PB-derived grafts noted that previously published trials reported only a short-term follow- Abbreviations: CI = confidence interval; CMML = chronic myelomonocytic leukemia; HR = hazard ratio; OR = odds ratio; RAEB = refractory anemia with excess blasts; RAEB-t = RAEB in transformation; sAML = secondary AML. Reproduced with permission from Kroger et al. up and were not well balanced between MUD and sibling donors. Therefore, two large, well designed prospective randomized studies with prolonged follow-up were conducted in parallel in Europe 68 and in North America. 69 Indeed, chronic but not acute GVHD was reported to be more frequent after PB-derived allo-HCT. With a median follow-up of 3 years in one study and 9 years in the other, differences were observed in OS and leukemia-free survivals, but did not reach statistical significance. Owing to the increased incidence of chronic GVHD in the PB arm in the US trial, the duration of immunosuppression therapy was longer and resulted in a higher GVHD-associated mortality rate; no such effect was observed in the European trial.
Conclusion: Care with interpreting data reported early after completion of study. Mature follow-up data are essential. Prolonged follow-up and OS as end points should be preferred. No clear preference can be made for using PB vs marrow based on outcomes for patients, but ease of collection and safety for donors will likely mean that PB will be the main source of stem cells for the near future.
IS A MATCHED SIBLING ALWAYS SUPERIOR TO AN ALTERNATIVE DONOR?
A 43-year-old male with very high-risk AML in CR1 and no comorbidities is referred to a center for consideration of allogeneic transplant. Available as donors are his matched fit 61-year-old sibling and a fully matched 25-year-old MUD (molecular matching for HLA-A, B, C, DR and DQ). Which donor is preferable?
Historically, results with a sibling matched donor were reported to be superior to MUD transplants. More recent data suggest that the outcomes from a MUD transplant appear more similar to those from a sibling donor transplant. Given the need for a potent GVL effect in this patient, and the presumed increased allelic disparity at minor HLA loci, it is tempting for clinicians to recommend a MUD donor in preference to a matched sibling. Many clinicians might also be swayed by the older age of the sibling donor when compared with the MUD, providing a further rationale for selecting the younger MUD. However, a close examination of the data is not supportive of such an approach.
Timing of allo-HCT is of importance and a prolonged donor selection process may affect its success. The time from patient referral to transplant is usually shorter for the persons who have a matched sibling donor as opposed to those who are in need of a MUD. A prolonged 'processing' period may be associated with a higher relapse rate for MUD transplants but conversely, it may preclude transplantation for patients with aggressive disease who deteriorate during the waiting period. This kind of bias was clearly demonstrated by Dini et al. 70 in ALL patients. Of 167 pediatric ALL patients in second remission assigned for MUD, only 60 patients eventually underwent transplant. The OS of this subgroup was significantly better than OS of all 167 patients (29.7% vs 10.9%) ( Figure 6 ). In addition, physicians are more apt to offer patients an allo-HCT if a matched sibling is available, so one can assume that retrospective MUD transplantation reports included patients who presented with more aggressive diseases.
The well-known association of acute or chronic GVHD with decrease in relapse rate may also lead to a bias. It should be recognized that although the risk for more severe GVHD is higher with MUD there is a poor correlation of relapse rate with severity or duration of GVHD, and the relationship between GvHD and GvL is not linear. 71, 72 This situation is also highlighted by the fact that GVL may occur in the absence of any clinical signs of GvHD.
Returning to our patient in question, there are relevant data from large analyses from the registries. In a large CIBMTR study of patients treated between 1995 and 2004, a superior leukemia-free survival was reported in patients following an HLA-identical sibling (n = 1271) compared to an unrelated donor transplant (n = 340), due not only to an elevated TRM rate but also to a higher relapse rate following MUD transplantation (a relative risk of 1.5; P = .002) (Figure 7 ). 73 These data were confirmed by another CIBMTR study for AML covering a later period, [2002] [2003] [2004] [2005] [2006] . In this study, too, there was no benefit for using a well-matched unrelated donor compared with a sibling in either relapse frequency or disease-free survival. 74 It is important to emphasize that both these large studies were adjusted for disease stage, white blood cell count at diagnosis, duration of CR1 and cytogenetics. Interestingly, similar data have also been published concerning RIC, where the GVL effect is critical. 56 The issue of whether a young MUD is better than an older sibling has also been studied in a CIBMTR trial; the data showed that an older sibling donor is still preferable, provided the sibling has a good performance status. 75 Similar data were confirmed in a recently published French study. 76 Thus, although in this patient it may be intuitive to prefer a young unrelated donor, the published data do not support such a choice.
Until the selection of unrelated donors undergoes further refinement, the best choice for a transplant remains a matched sibling donor. Interpreting outcome data Y Ofran et al CONCLUSION Prospective transplant clinical trials are scarce. The outcome of allo-HCT reported from retrospective and registry-based studies is complicated and difficult to interpret owing to multiple indications, conditioning and donor selection options. Predicting specific patient's chances to benefit from allo-HCT cannot be merely extrapolated from published data owing to inherent biases resulting from various referral practices and differences in patients' history, pretransplant waiting time and therapies. In addition, a common caveat regarding the ultimate usage of allo-SCT is the patients' and physicians' fears of common allo-HCT related toxicities. However, it is imperative that although substantial, adverse allo-SCT outcomes should be considered in the context of expected patient outcomes and toxicities with alternative therapies. Allo-HCT should be recommended if a clear OS benefit is projected even when other less toxic but less effective options are available (for example, intermediate-risk acute leukemia in CR1) and not when all options including allo-HCT carry dismal prognosis (for example, very high-risk AML or very advanced other hematological malignancies). Large studies with prolonged follow-up should be encouraged, but inevitably many clinical dilemmas evolving from the rapid introduction of novel drugs, genetic insights and transplant practices will be difficult to address in a timely fashion. Use of allo-SCT in very highrisk situations where it is not supported by data, but is nevertheless offered owing to lack of alternative therapy should be discouraged. Short and long-term risks from disease and competing therapies should always be discussed in the context of a patient's personal preferences and goals.
